Tenofovir Antiviral Therapy Following Transarterial Chemoembolization for HBV Related Hepatocellular Carcinoma

Hepatocellular Carcinoma Clinical Trial

Official title:

Tenofovir Disoproxil Fumarate Improves Outcomes Following Palliative Transarterial Chemoembolization for Hepatitis B Virus Related Hepatocellular Carcinoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01872988
• Other study ID #: CF12045
• Secondary ID: JIRB11-036-A
• Status: Terminated
• Phase: Phase 3
• First received: January 30, 2013
• Last updated: September 3, 2014
• Start date: September 2012
• Est. completion date: February 2018

Study information

• Verified date: September 2014
• Source: Taichung Veterans General Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Interventional

Clinical Trial Summary

Hepatocellular carcinoma (HCC) is one of the most common solid cancers worldwide, and chronic hepatitis B virus (HBV) infection is the most common etiology of HCC in Asia. Transarterial chemoembolization (TACE) is the standard treatment for patients with unresectable HCC in the BCLC intermediate stage, but the HCC recurrence rates and long-term mortality rates are quite high. These intermediate-staged HCC patients usually need repeated TACE due to tumor recurrence, and they may die of HCC progression or liver decompensation after repeated TACE. Improved liver function and decreased liver disease progression due to oral antiviral therapy have been proven to be effective for chronic hepatitis B, and oral antiviral therapy may keep better liver reserve and provide better chance for HCC patients received TACE. In addition, chronic HBV infection is one of the most important factors for HCC development, and antiviral therapy can improve the outcomes after curative treatment. However, the evidence of improving outcomes of HCC patients underwent TACE by oral antiviral therapy is lacking. Moreover, Tenofovir Disoproxil Fumarate (TDF) is one of the most potent oral antiviral agents, and its safety and very low long-term viral resistance rate have been also reported. There is no study to evaluate the impacts of TDF for HBV-related HCC patients underwent TACE. Until now, routine antiviral therapy for HBV-related HCC patients underwent TACE has still not been recommended by current guidelines. The hypothesis of this study is that a potent oral antiviral therapy for patients with HBV-related HCC patients receiving TACE improve patients' outcomes

Description:

This is randomized double-blind placebo-controlled trial that will be conducted in referral teaching hospitals in Taiwan. This trial will recruit 320 patients fulfilling all of the following criteria: patients more than 20 years old, HCCs diagnosed by AASLD image criteria or pathology, medium-sized HCCs in BCLC intermediate stage and not more than 5 cm in maximum diameter and not more than 5 tumors that TACE is indicated, chronic HBV carrier (HBsAg+) with detectable HBV DNA in blood, ECOG performance status (PST) 0-2, Child-Pugh score ≦7, serum bilirubin < 2 mg/dL and prothrombin time (PT) prolongation < 3 seconds, and willingness to adhere to treatment and follow-up plans. Patients are ineligible if they have any of the following exclusion criteria: any vascular invasion by tumors, extra-hepatic metastasis, concurrent any other malignancy, concomitant immunosuppressive therapy, previous any HCC treatment, previous or current any antiviral therapy for HBV, concomitant other therapies for HCC except TACE, liver cirrhosis with severe gastroesophageal varices (EVF3 or with red color sign), poorly-controlled ascites or hepatic encephalopathy, contraindication for invasive procedures such as recent gastrointestinal bleeding or cerebral hemorrhage, contraindication to TACE such as allergy to contrast, pregnancy, sepsis, etc., chronic renal failure with eGFR < 60, concurrent any other chronic viral hepatitis with HCV, HDV, or HIV). The Primary endpoints of this study will be 1-, 3-year overall survival, and the secondary endpoints of this study will be time to tumor progression and time to liver decompensation.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 320
• Est. completion date: February 2018
• Est. primary completion date: February 2018
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. more than 20 years old

2. HCCs diagnosed by AASLD image criteria or pathology

3. Intermediate-stage HCCs that TACE is indicated

4. chronic HBV carrier with detectable HBV DNA in blood

5. ECOG performance status (PST) 0-2

6. Child-Pugh score ?7

7. serum bilirubin < 2 mg/dL

8. prothrombin time prolongation < 3 seconds

9. willingness to adhere to treatment and follow-up plans -

Exclusion Criteria:

1. any vascular invasion by tumors

2. extra-hepatic metastasis

3. concurrent any other malignancy

4. concomitant immunosuppressive therapy

5. HCC recurrence within 2 years of previous curative treatment

6. antiviral therapy for chronic hepatitis B within 6 months before HCC diagnosis

7. concomitant other therapies for HCC except TACE

8. liver cirrhosis with severe gastroesophageal varices (EVF3 or with red color sign), poorly-controlled ascites or hepatic encephalopathy

9. contraindication for invasive procedures such as recent gastrointestinal bleeding or cerebral hemorrhage

10. contraindication to TACE such as allergy to contrast, pregnancy, sepsis, etc.

11. chronic renal failure with eGFR < 60

12. concurrent any other chronic viral hepatitis with HCV, HDV, or HIV) -

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Chronic Hepatitis B
• Hepatitis
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic
• Hepatocellular Carcinoma

Intervention

Drug:
• Tenofovir
Administer Tenofovir to HCC patients who are indicated for TACE after randomization
• Placebo
Administer Placebo to HCC patients who are indicated for TACE after randomization

Locations

Country	Name	City	State
Taiwan	Chia-Yi Christine Hospital	Chia-Yi
Taiwan	E-Da Hospital	Kaohsiung
Taiwan	Taichung Veterans General Hospital	Taichung
Taiwan	Mackay Memorial Hosp	Taipei

Sponsors (3)

Lead Sponsor	Collaborator
Taichung Veterans General Hospital	Gilead Sciences, Taipei Institute of Pathology

Country where clinical trial is conducted

Taiwan, 

References & Publications (2)

Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002 May 18;359(9319):1734-9. — View Citation

Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, Fan ST, Wong J. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002 May;35(5):1164-71. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	overall survival		up to 3-year	Yes
Secondary	time to tumor progression		1- and 3-year	No
Secondary	time to liver decompensation		1- and 3-year	Yes

External Links

•   The Institutional Review Board of Taichung Veterans General Hospital